Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc, is shown in Cambridge, Massachusetts (Photographer: JB Reed/Bloomberg News ) 

Lupin, Sun Pharma, Glenmark Recall Products In The U.S.

Indian drugmakers Lupin Ltd., Sun Pharmaceutical Industries and Glenmark Pharmaceuticals Ltd. are recalling various drugs from the U.S. market for a variety of reasons.

As per the latest Enforcement Report published by the U.S. Food and Drug Administration, Lupin is voluntarily recalling 55,000 vials and over 1.6 lakh boxes of anti-bacterial drug Ceftriaxone for injection in various strengths.

The recall has been initiated by Lupin Pharmaceuticals, Inc., a subsidiary of the Mumbai-based firm. The products have been manufactured at the company's facility in Mandideep, Madhya Pradesh. The company is recalling specific lots of drugs due to the presence of particulate matter.

"Product complaints received of grey flecks, identified as shredded rubber particulate matter from the stopper observed in reconstituted vials," U.S. FDA said. The ongoing voluntary nationwide recall has been classified as Class-I. Such recalls are for dangerous or defective products that predictably could cause serious health problems.

Lupin Pharmaceuticals is also recalling 2.8 lakh bottles of Cefdinir for Oral Suspension, used to treat bacterial infections, under Current Good Manufacturing Practice deviations.

Also read: USFDA Inspecting Sun Pharma’s Injectibles Plant

The U.S. FDA has classified it as a Class-II recall, which is initiated in a "situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”

Similarly, Sun Pharma is voluntarily recalling 13,918 cartons and over 1.39 lakh vials of Vecuronium Bromide for Injection, used as part of general anesthesia, due to presence of particulate matter.

Besides, Glenmark Pharmaceuticals is recalling 96,240 applicators of its product Estradiol Vaginal Inserts for defective delivery system. The U.S. FDA has termed it as a Class-II recall.